Pfizer’s Embeda Joins Abuse-Deterrent Club, But FDA Wants Assurances
This article was originally published in The Pink Sheet Daily
Executive Summary
As with Purdue’s Targiniq, agency requires a post-marketing study to determine whether the new morphine/naltrexone formulation actually deters abuse.